IF YOU’RE A POTENTIAL PARTNER
Series A or government funding for Phase 1/2a Orlance MACH-1® influenza or CoV vaccine
DNA and mRNA vaccine Phase 1 candidates
Kristyn Aalto, CEO
206-792-5069
kaalto@orlance.com
Our Team
Orlance, inc
Kris Alto
CEO
25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.
Deb Fuller
PhD, CTO
co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.
Jim Mullins
PhD
co-founder and SAB member, UW, molecular and computational approaches vaccine design, the originator of conserved element (CE) approach to vaccine development.
Ken Bagley
PhD, Dir. R&D
15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.
Hannah Frizzell
PhD
Bioengineer, Immunology, and nano delivery system experience.